ALEXANDRIA CENTERS EXPERIENCE IN THE EXTENDED ADJUVANT HORMONAL THERAPY IN BREAST CANCER

Document Type : Preliminary preprint short reports of original research

Authors

1 Department of Oncology and Nuclear Medicine, Faculty of Medicine, University of Alexandria, Egypt

2 Department of Clinical Oncology, Faculty of Medicine, University of Alexandria

Abstract

INTRODUCTION
Breast cancer (BC) is the most common and second-leading cause of mortality among female cancers.
Endocrine therapy (ET) has been recognized as a substantial and successful adjuvant therapy for women with HR+ early-stage breast cancer. Adjuvant ET is suggested for ER+ patients to improve OS and reduction of breast cancer recurrence. The treatment of choice for women before and after menopause is tamoxifen therapy for five years.
Combinations of AIs with tamoxifen are one of the newer alternative therapy regimens that have evolved in the previous few decades. In major randomized studies of postmenopausal individuals, adjuvant treatment with AIs (letrozole, anastrozole, or exemestane) for 5 years (instead of tamoxifen) or for 2-3 years after 3-2 years of tamoxifen increased disease free survival compared to tamoxifen alone.
Additionally, the length of treatment is crucial since side effects such as hot flashes, bone pain, bone density loss, arthropathy, depression, and exhaustion may occur with adjuvant endocrine therapy. Testing the safety and efficacy of extended adjuvant hormonal therapy for hormone receptor positive breast cancer patients was the driving force for this study.
AIM OF THE WORK
To retrospectively assess the efficacy and toxicity of extended adjuvant Hormonal therapy in hormone receptor positive breast cancer patients includes:
 Disease free survival including local recurrence and distant metastases
 Complications related to the treatment.
 Toxicity scored according to CTC v.4

Keywords

ALEXMED ePosters
Volume 6, Issue 4
September 2024
Pages 68-69

Files

Share

How to cite

Statistics